What is Tensive?
Founded in 2012, Tensive S.r.l. is at the forefront of developing advanced bioresorbable scaffolds designed for natural breast reconstruction and augmentation. The company's flagship product, REGENERA, is engineered to enhance the quality of life for breast cancer survivors by offering a safe and effective solution for breast restoration post-lumpectomy. Tensive is actively engaged in clinical investigations to bring its groundbreaking biomaterials technology to a global market, focusing on improving clinical outcomes for patients worldwide.
How much funding has Tensive raised?
Tensive has raised a total of $560K across 1 funding round:
Private Equity
$560K
Private Equity (2016): $560K with participation from Invitalia Ventures and Unicredit
Key Investors in Tensive
Invitalia Ventures
Invitalia Ventures is the venture capital arm of Invitalia, Italy's national development agency. They focus on financing innovative projects and startups, particularly those with high growth potential and national economic impact.
Unicredit
Unicredit is a major European banking group, providing a wide range of financial services. Their investment in Tensive likely reflects an interest in supporting innovative companies within the healthcare and technology sectors.
What's next for Tensive?
With this major strategic investment, Tensive is poised to accelerate its product development and market entry. The enterprise-level funding suggests a focus on scaling operations, expanding clinical trials, and preparing for commercialization. This backing will likely enable Tensive to further its mission of enhancing accessibility and clinical outcomes through its advanced biomaterials, positioning it for significant growth in the reconstructive surgery and medical device sectors.
See full Tensive company page
